Lipid vesicles bearing carbohydrate surfaces as lymphatic directed vehicles for therapeutic and diagnostic substances
First Claim
1. Phospholipid vesicles comprising a lipid bilayer which includes:
- a cell-surface receptor selected from synthetic sugar and amino sugar derivatives of cholesterol, andcholesterol, andan effective amount of physiologically compatible radioactive tracer, cytotoxic or therapeutic agent as a part of the vesicles.
0 Assignments
0 Petitions
Accused Products
Abstract
Lipid vesicles comprising a lipid bilayer which includes analogs of cell-surface receptors such as dicetyl phosphate; stearylamine; 6-(5-cholesten-3β-yloxy) hexyl 1-thio-β-L-fucopyranoside; 6-(5-cholesten-3β-yloxy) hexyl 1-thio-β-D-galactopyranoside; 6-(5-cholesten-3β-yloxy)hexyl 1-thio-α-D-mannopyranoside; 6-(5-cholesten-3-yloxy)hexyl 2-acetamido-2-deoxy-1-thio-β-D-galactopyranoside; 6-(5-cholesten-3β-yloxy)hexyl 6-amino-6-deoxy-1-thio-β-D-galactopyranoside; or 6-(5-cholesten-3β-yloxy)hexyl 6-amino-6-deoxy-1-thio-α-D-mannopyranoside; cholesterol and distearoyl phospatidylcholine, and an effective amount of physiologically compatible radioactive tracer, cytotoxic or therapeutic agent as a part of the vesicles. The vesicles of this invention can be administered to the human host and have been found to release the contents of the vesicles in a predetermined manner, i.e., controlled release, and in some cases, to be rapidly concentrated in the lymphatic system and/or liver, lungs or spleen of the host.
156 Citations
8 Claims
-
1. Phospholipid vesicles comprising a lipid bilayer which includes:
-
a cell-surface receptor selected from synthetic sugar and amino sugar derivatives of cholesterol, and cholesterol, and an effective amount of physiologically compatible radioactive tracer, cytotoxic or therapeutic agent as a part of the vesicles. - View Dependent Claims (2, 3, 4)
-
-
5. The method comprising administering to the mammalian host phospholipid vesicles comprising a lipid-bilayer which includes:
-
a cell surface receptor selected from synthetic sugar and amino sugar derivatives of cholesterol, and cholesterol, and an effective amount of physiologically compatible radioactive tracer, cytotoxic or therapeutic agent as a part of the vesicles, said phospholipid vesicles being further characterized by the rapid intact accumulation in the lymphatic system and/or lungs, spleen or liver. - View Dependent Claims (6, 7, 8)
-
Specification
-
- Resources
-
Current AssigneeCalifornia Institute of Technology
-
Original AssigneeCalifornia Institute of Technology
-
InventorsGamble, Ronald C., Baldeschwieler, John D., Ponpipom, Mitree M., Shen, Tsung-Ying, Mauk, Marcia R.
-
Primary Examiner(s)Nucker, Christine M.
-
Application NumberUS06/092,342Time in Patent Office796 DaysField of Search424/1, 424/1.5, 424/35, 424/9, 252/316, 252/319US Class Current424/1.21CPC Class CodesA61K 9/127 LiposomesA61K 9/1271 Non-conventional liposomes,...A61K 9/1272 with substantial amounts of...Y10T 428/2984 Microcapsule with fluid cor...
